Mejia Andres F, Culp Timothy D, Cladel Nancy M, Balogh Karla K, Budgeon Lynn R, Buck Christopher B, Christensen Neil D
Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033-2390, USA.
J Virol. 2006 Dec;80(24):12393-7. doi: 10.1128/JVI.01583-06. Epub 2006 Sep 27.
A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.
一种由病毒样颗粒（VLP）组成的人乳头瘤病毒（HPV）疫苗最近被批准用于人类。一般认为，VLP疫苗通过诱导型特异性中和抗体来提供保护。由于物种限制，临床前动物模型不能用于测试针对HPV感染的保护作用。我们开发了一种使用嵌合HPV衣壳/棉尾兔乳头瘤病毒（CRPV）基因组颗粒的模型，以允许在兔体内直接测试HPV VLP疫苗。用CRPV、16型HPV（HPV-16）或HPV-11 VLP疫苗接种的动物，分别用同源（CRPV衣壳）和嵌合（HPV-16衣壳）颗粒进行攻击。观察到了强烈的型特异性保护作用，证明了该方法的潜在应用价值。
